万邦德：子公司阿尔茨海默病项目入选国家科技重大专项

Core Viewpoint - Wanbangde's subsidiary, Wanbangde Pharmaceutical Group, has been selected for a national major science and technology project led by the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, focusing on innovative drug development for Alzheimer's disease [1] Group 1 - The Alzheimer's disease project involves the development of a new drug, Shisuanjianma Controlled-Release Tablets, which is currently undergoing large-scale, high-quality key registration Phase II/III clinical studies [1]